MIRA Pharmaceuticals: Oral Mira-55 normalized pain, reduced inflammation, outperforming injected morphine

MIRA PHARMACEUTICALS, INC.

Oral Mira-55 normalized pain thresholds to baseline and reduced paw edema in formalin-induced chronic pain model, outperforming injected morphine.
Mira-55 showed direct CB2-receptor-mediated anti-inflammatory effect; morphine only partial indirect effect.
First study to directly measure inflammation alongside pain; supports planned IND for chronic inflammatory pain.
Company targeting $70 billion non-opioid pain market with dual-mechanism drug addressing both cause and perception of pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.